Adaptive Biotechnologies (ADPT) Current Deferred Revenue (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Current Deferred Revenue data on file, last reported at $49.4 million in Q1 2026.

• Quarterly Current Deferred Revenue fell 9.87% year-over-year to $49.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.4 million (down 9.87% YoY) and the FY2025 annual result came in at $46.2 million, down 44.3% from the prior year.
• Current Deferred Revenue improved to $49.4 million in Q1 2026 per ADPT's latest filing, from $46.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $155.0 million in Q2 2022, with the low at $41.3 million in Q3 2025.
• Average Current Deferred Revenue over 5 years is $70.1 million, with a median of $57.9 million recorded in 2023.
• Year-over-year, Current Deferred Revenue surged 85.55% in 2022 and sank 62.64% in 2023.
• Adaptive Biotechnologies' Current Deferred Revenue stood at $64.1 million in 2022, then fell by 24.15% to $48.6 million in 2023, then jumped by 70.56% to $82.9 million in 2024, then sank by 44.3% to $46.2 million in 2025, then advanced by 6.92% to $49.4 million in 2026.
• Business Quant data shows ADPT's Current Deferred Revenue at $49.4 million in Q1 2026, $46.2 million in Q4 2025, and $41.3 million in Q3 2025.